great info site

[Guest guest]

Hi Yoly-

Here are a few sites that you will find helpful-

here is Dr. LaGrone's website:

http://www.scoliosismd.com/

and some other helpful sites, excellant explanations done by a flatback

patient

http://www.microconn.com/scoliosis/flatback_syndrome.htm

excellantcomplex spine surgery doc in NYC ( ofc in NJ too)

http://www.erricospine.com

wishing you many peaceful moments

TwistedSister in NJ

1982 Scoliosis Harrington fusion, 1998 Revision A/P Surgery for Flatback

Syndrome, 1998 Post Traumatic Stress Disorder, 1999 Degenrative SI Joints,

2000 Weight Loss Surgery, 2000 Spinal Hardware Removed, 2001 Cervical

bulging discs, 2002 Arachnoiditis, 2002 GERD, 2002 Adhesions, 1993 Mitral

Valve Prolapse, 1996 Fibromyalgia, 2001 Kidney Stones,

2003 Interstitial Cystitis, May 2003 anterior spine hardware removal

** LIFE IS UNCERTAIN.............EAT DESSERT FIRST **

Harrington Rod scoliosis people and other post-op multiple spine surgery

people may interested in the following website dedicated to Flatback

Syndrome and revision/salvage spine surgery... " Salvaged Sisters of

Scoliosis " website on Delphi Forums at:

http://forums.delphiforums.com/adultscoliosis/messages

[Guest guest]

Understanding Healing Crisis Printable Version (by permission only) When I hit a healing crisis and started to detox, I quit using herbs. I thought the herbs were making things worse, thank goodness, out of desperation I returned to those herbs, rode out the cleansing and healing process and now enjoy better health than I had when I was 22 years old. Many people are caught off guard and fail to understand and interpret the symptoms and changes which follows a change to a healthier lifestyle. Many of these symptoms and changes are unpleasant but they are short in duration and are sporadic and are a necessary part of the healing process. There are several reasons why this happens: #1 The body and mind begin to show changes because the quality of

nutrients coming into the body is of higher, quality than the the tissue of which the body is made. The body begins to discard the lower grade materials to make room for the superior materials. The discarding of the material can come through the bowel causing diarrhea, through the kidney causing back ache, through the respiratory system causing a cold or through the skin causing boils, acne, rashes, psoriasis, etc. #2 Indigestion, heartburn, flatulence, bloating and burping usually starts soon after you start herbs. This happens because your body is not used to digesting these nutrients which often indicates that you have been deficient of these nutrients for a long time. The body's digestion usually improves in a week or two. Taking the herbs with meals or with papaya mints will often help. #3 Suppressed body functions will be stimulated to detoxify the body, sometimes inducing colds, diarrhea, fevers, swelling, acne, boils and vomiting.

This is temporary and is part of the healing process. The body will return to at least the same level of health as before if not superior health UNLESS you do something to suppress this progress. #4 Nervousness, headaches, fatigue, irritability and depression often happen when you cut out any artificial stimulants such as sugar, chocolate, coffee, tea, soda, tobacco, caffeine or recreational drugs. You will not get the desired result if you substitute one artificial stimulant for another. It is important at this time to rest and sleep more. Once the artificial stimulants are eliminated the body is ready for the building process. The energy of a healthy, well nourished body is superior to any artificial stimulant. #5 Moderate weight fluctuation often occurs (either weight loss or weight gain). If you continue the healthier lifestyle the weight will stabilize. #6 Skin eruptions, warts, boils or acne. The skin is the largest

eliminating organ, so the concept of toxins coming out through the skin is easily understood, even if it is hard to face. #7 Aches, pains and arthritis will often get stirred up, even if you haven't been suffering with it for years. This happens because uric acid and toxins aggravate these conditions as they are cleansed from the body. #8 Fevers are not uncommon when dormant bacteria and virus are being cleaned out. This sounds discouraging, but the healing crisis doesn't last very long and the benefits of cleaning the body of these toxins and disease elements are vitally important. These bacteria, virus or toxins are going to show up sooner or later. You can either have a healthy body handle them on your terms or it will come out when it

overpowers your weakened body. It is better to go through small healing crises than a full blown health crisis. If you are in doubt about whether what you are experiencing is a normal part of healing contact a competent health professional. The focus of this site is to "educate, validate, and suggest alternative methods for the treatment of health conditions," which are not readily available to those who go through mainstream programs. To help ensure good results, high quality foods and supplements are vital. Knowing that the cost of supplements can get overwhelming, we provide a wholesale store. This is a courtesy, not a requirement for you to ask your questions. We are here to help people, not just gain customers. If you have any questions please feel free to contact me. ***When working with natural health it is beneficial that you have an understanding of the signs of a healing body. *** Dr. (Gates), CNHP, MH, ND626 Donnelly AvePatton, PA 16668Phone: 814-674-8835© 1990-2005, Dr. (Gates) All rights reservedelizabethnv1 <elizabethnv1@...> wrote: HCV-796 Displays Potent Antiviral Activity in Replicon and in Chimeric Mice Infected with Hepatitis C Virus (HCV)Reported by Jules LevinICAACSan Francisco, Sept 27-30, 2006There are abstracts on several new HCV drugs at ICAAC. Today, there is a poster on MK-0608, a promising HCV nucleoside, which showed potency in 7-day study results in chimps reported at the HIV Drug Resistance Workshop this Summer. Although the poster will be displayed today a summary was printed in the abstract book showing results of 37 days of therapy in chimps, and the results are very good. I will report the poster results later today

afyer viewing it in about 1 hour. Also presented at this meeting were posters on HCV polymerase inhibitors in development by Roche and Abbott. R1626 is the Roche polymerase inhibitor for which study results in patients were reporred this Spring showing a 1.2 log reduction in patients after 14 days of monotherapy. Further study results will be reported at AASLD. Abbott is in pre-clinical development for a HCV drug.A. Y. M. HOWE1, N. M. KNETEMAN 2,3, T. GAO 2, J. LEWIS 3, M. COLLETT 4, D. PEVEAR 4, D. L. J. TYRRELL 2,3, J. F. O'CONNELL 1; 1Wyeth Res., Collegeville, PA, 2KMT Hepatech, Inc., Edmonton, Canada, 3Univ. of Alberta, Edmonton, Canada, 4ViroPharma, Inc., Exton, PA.HCV-796, a non-nucleoside HCV polymerase inhibitor, demonstrates potent antiviral activity in vitro and in a small animal model of HCV replication. IntroductionSince the initial report of its development (1), the SCID/beige-Alb/uPA

human hepatocyte chimeric mouse model, infected with hepatitis C virus, has been successfully employed to test a number of anti-viral compounds, including interferon a-2b, the NS3 protease inhibitor BILN-2061 and the NS5B polymerase inhibitor HCV-371 (2). Results obtained from the mouse model have successfully predicted outcomes from human clinical trials, both for positive (BILN-2061) and negative (HCV-371) outcomes.HCV-796, an orally dosed hepatitis C viral polymerase inhibitor developed from a different chemical series than HCV-371, has now been evaluated in in vitro and in vivo studies for anti-viral activity.The following studies were carried out with the animal model system and biochemical assays:--RNA dependent RNA polymerase inhibition assays and subgenomic replicon assays (study 1)--a pilot, proof-of-concept study of the anti-viral activity of HCV-796 at one dose in HCV infected chimeric mice

(study 2)--assessment in infected chimeric mice of the antiviral activity of HCV-796 compared to IFN a-2b or vehicle control (study 3)--assessment in infected chimeric mice of the antiviral activities of HCV-796 or IFN a-2b alone or in combination with each other (study 4) STUDY 1: In Vitro activity profile of HCV-796In vitro antiviral activity was evaluated in HCV replicon cells. Polymerase inhibition assays revealed an IC50 of 0.01 - 0.16 uM for genotype 1 and 0.22 - 1.7 uM for genotype 2, 3 and 4. In an in vitro subgenomic replicon assay, HCV=796 specifically reduced steady state levels of HCV RNA with IC50s of 5nM & 9 nM against genotypes 1a and 1b (Therapeutic Index >1100) and also reduced HCV protein. In the 1a replicon assay, HCV-796 reduced HCV RNA levels 3-4 log10 HCV copies/_g total RNA (EC50=4.5nM). Study 2 design: Pilot study of HCV-796 anti-viral activity in chimeric micedose:

50 mg/kg/doseadministration: 3 times a day, oralcourse: 5 days treatmentstudy animals: HCV-796: 6. Control: 6Assays: hAAT for monitoring human hepatocyte grafts, Taqman ABI 7300 real time PCR for HCV RNA quantification.RESULTS--mean serum HCV viral RNA decreased by 2.02 +/- 0.55 log after 5 days therapy in HCV-796 treatment group--HCV viral RNA level remained stable in vehicle control (3.94 +/- 0.8 to 3.71 +/- 1.0)--A significant difference in the net decrease of HCV viral RNA existed between HCV-796 and vehicle control (p=0.01, two-sided (unpaired) t-test).Study 3 design: Effect of polymerase inhibitor HCV-796 and IFN on HCV titer in chimeric miceDose: HCV-796 50/mg/kg per doseInterferon a-2b (IFN): 1350 IU/gm/dayAdministration: HCV-796 and vehicle 3 times per day by oral gavage; IFN once per day i.m.Course: 10 days treatmentStudy animals: 5 each of HCV-796, IFN and vehicle control

groupsAssays: hAAT for monitoring human hepatocyte grafts; Taqman ABI 7300 real time PCR for HCV RNA quantificationRESULTS--mean HCV viral RNA decreased 1.78 +/- 0.27 log after 10 day treatment course with HCV-796 versus 0.35 +/- log decrease in vehicle control (p=0.009)--mean HCV viral RNA decreased 1.11 +/- 0.2 log after 10 days treatment with IFNa-2b (p=0.04 vs vehicle control)--HCV viral titer rebounded in all HCV-796 treated animals following end of treatment (data not shownStudy 4 design: HCV-796 and Interferon a-2b combination study in chimeric miceDose: HCV-796 30/mg/kg/dose alone or combined with 1350 IU/gm IFNAdministration: HCV-796 3 doses daily by oral gavage; IFN daily i.m.Course: 18 days treatmentStudy animals: HCV-796: 7; IFN: 7, IFN+hCV-796 combination: 8; vehicle control: 7Assays: hAAT for monitoring human hepatocyte grafts, Taqman ABI 7300 real time PCR for HCV

quantificationRESULTS--On day 11, mean serum HCV viral NA decreased by 0.66 +/-0.16 log )HCV-796 30 mg/kg, p=0.013), 1.35 +/- 0.14 log (IFN 1350 IU/gm, p=0.0001), and 2.44 +/- 0.23 (IFN + HCV-796 combination, p=0.0001) versus 0.12 +/- 0.22 increase in vehicle control after 10 days of treatment--Serum HCV viral RNA titer reduction after 10 days of therapy was significantly greater in the combination group compared to the grouos receiving IFN or HCV-796 alone (p<0.05)In the SCID mouse model, mean plasma concentrations at 8 hr after a single dose and dosing for 5 days with 50 mg/kg were 5- and 12-fold, respectively, above replicon EC50 (t1/2=2hr). The specific antiviral activity of HCV-796 is further confirmed by the viral rebound to baseline within 1 week of stopping treatment. The authors summarized: HCV-796 represents a potential antiviral for the treatment of HCV infection in humans. HCV-796, a

novel non-nucleoside inhibitor of the hepatitis C virus RNA-dependent RNA polymerase, demonstrated specific polymerase activity with IC50 values of 0.01 - 0.16 uM against genotype 1 and IC50 values of 0.22 to 1,7 uM against genotype 2, 3, and 4 enzymes. The compound also exhibited high activity in replicon systems and multiple treatments of genotype 1b replicon cells yielded a 3 to 4 log reduction in HCV viral RNA levels. The in vitro activity paralled in vivo results obtained with the HCV-infected chimeric mouse model. The mean HCV viral load in mice was reduced by 1.78 to 1.88 log after 5 to 10 days therapy with 50 mg/kg dose of HCV-796 compared to a mean 1.11 log decrease obtained with interferon a-2b treatment for 10 days. The combination of 30 mg/kg HCV-796 with interferon a-2b (1350IU/gm/day) resulted in a mean 2.44 log decrease in HCV viral RNA which was significantly greater than the decrease obtained with

either HCV-796 or interferon a-2b alone (0.66 or 1.35 log, respectively; p<0.05).This small animal model has previously proven predictive of clinical treatment impact for antiviral compounds for HCV as demonstrated by positive outcomes in the mouse model with interferon a-2b and a protease inhibitor (BILN-2061) and by negative outcomes with a polymerase inhibitor HCV-371 in both the mouse model (2) and a phase 1b clinical trial (4).The predictive value of the mouse model has now also been confirmed by the positive outcomes with HCV-796 in the model and in vitro studies and the recently announced preliminary data from a clinical phase 1b trial of HCV-796 and pegylated interferon combination therapy in which a mean viral load reduction across all combination groups of between 3.3 to 3.5 log was obtained at day 14 compared to a 1.7 log decrease obtained with interferon alone

(6).Tim Parsons knoxville,tn 37931 865-588-2465 x107 work

www.knoxville1.com

All-new - Fire up a more powerful email and get things done faster.

[Guest guest]

another GREAT article!Hillbilly Tim <knoxweb1@...> wrote: Understanding Healing Crisis Printable Version (by permission only) When I hit a healing crisis and started to detox, I quit using herbs. I thought the herbs were making things worse, thank goodness, out of desperation I returned to those herbs, rode

out the cleansing and healing process and now enjoy better health than I had when I was 22 years old. Many people are caught off guard and fail to understand and interpret the symptoms and changes which follows a change to a healthier lifestyle. Many of these symptoms and changes are unpleasant but they are short in duration and are sporadic and are a necessary part of the healing process. There are several reasons why this happens: #1 The body and mind begin to show changes because the quality of nutrients coming into the body is of higher, quality than the the tissue of which the body is made. The body begins to discard the lower grade materials to make room for the superior materials. The discarding of the material can come through the bowel causing diarrhea, through the kidney causing back ache, through the respiratory system causing a cold or through the skin causing boils, acne, rashes, psoriasis, etc. #2 Indigestion, heartburn,

flatulence, bloating and burping usually starts soon after you start herbs. This happens because your body is not used to digesting these nutrients which often indicates that you have been deficient of these nutrients for a long time. The body's digestion usually improves in a week or two. Taking the herbs with meals or with papaya mints will often help. #3 Suppressed body functions will be stimulated to detoxify the body, sometimes inducing colds, diarrhea, fevers, swelling, acne, boils and vomiting. This is temporary and is part of the healing process. The body will return to at least the same level of health as before if not superior health UNLESS you do something to suppress this progress. #4 Nervousness, headaches, fatigue, irritability and depression often happen when you cut out any artificial stimulants such as sugar, chocolate, coffee, tea, soda, tobacco, caffeine or recreational drugs. You will not get the desired result if

you substitute one artificial stimulant for another. It is important at this time to rest and sleep more. Once the artificial stimulants are eliminated the body is ready for the building process. The energy of a healthy, well nourished body is superior to any artificial stimulant. #5 Moderate weight fluctuation often occurs (either weight loss or weight gain). If you continue the healthier lifestyle the weight will stabilize. #6 Skin eruptions, warts, boils or acne. The skin is the largest eliminating organ, so the concept of toxins coming out through the skin is easily understood, even if it is hard to face. #7 Aches, pains and arthritis will often get stirred up, even if you haven't been suffering with it for years. This happens because uric acid and toxins aggravate these conditions as they are cleansed from the body. #8 Fevers are not uncommon when dormant bacteria and virus are being cleaned out. This sounds discouraging, but the healing crisis doesn't last very long and the benefits of cleaning the body of these toxins and disease elements are vitally important. These bacteria, virus or toxins are going to show up sooner or later. You can either have a healthy body handle them on your terms or it will come out when it overpowers your weakened body. It is better to go through small healing crises than a full blown health crisis. If you are in doubt about whether what you are experiencing is a normal part of healing contact a competent health professional. The focus of this site is to "educate, validate, and suggest alternative methods for the treatment of health conditions," which are not readily available to those who go through mainstream programs. To help ensure good results, high quality foods and supplements are vital. Knowing that the cost of

supplements can get overwhelming, we provide a wholesale store. This is a courtesy, not a requirement for you to ask your questions. We are here to help people, not just gain customers. If you have any questions please feel free to contact me. ***When working with natural health it is beneficial that you have an understanding of the signs of a healing body. *** Dr. (Gates), CNHP, MH, ND626 Donnelly AvePatton, PA 16668Phone: 814-674-8835© 1990-2005, Dr.

(Gates) All rights reservedelizabethnv1 <elizabethnv1earthlink (DOT) net> wrote: HCV-796 Displays Potent Antiviral Activity in Replicon and in Chimeric Mice Infected with Hepatitis C Virus (HCV)Reported by Jules LevinICAACSan Francisco, Sept 27-30, 2006There are abstracts on several new HCV drugs at ICAAC. Today, there is a poster on MK-0608, a promising HCV nucleoside, which showed potency in 7-day study results in chimps reported at the HIV Drug Resistance Workshop this Summer. Although the poster will be displayed today a summary was printed in the abstract book showing results of 37 days of therapy in chimps, and the results are very good. I will report the poster results later today afyer viewing it in about 1 hour. Also

presented at this meeting were posters on HCV polymerase inhibitors in development by Roche and Abbott. R1626 is the Roche polymerase inhibitor for which study results in patients were reporred this Spring showing a 1.2 log reduction in patients after 14 days of monotherapy. Further study results will be reported at AASLD. Abbott is in pre-clinical development for a HCV drug.A. Y. M. HOWE1, N. M. KNETEMAN 2,3, T. GAO 2, J. LEWIS 3, M. COLLETT 4, D. PEVEAR 4, D. L. J. TYRRELL 2,3, J. F. O'CONNELL 1; 1Wyeth Res., Collegeville, PA, 2KMT Hepatech, Inc., Edmonton, Canada, 3Univ. of Alberta, Edmonton, Canada, 4ViroPharma, Inc., Exton, PA.HCV-796, a non-nucleoside HCV polymerase inhibitor, demonstrates potent antiviral activity in vitro and in a small animal model of HCV replication. IntroductionSince the initial report of its development (1), the SCID/beige-Alb/uPA human hepatocyte chimeric mouse model,

infected with hepatitis C virus, has been successfully employed to test a number of anti-viral compounds, including interferon a-2b, the NS3 protease inhibitor BILN-2061 and the NS5B polymerase inhibitor HCV-371 (2). Results obtained from the mouse model have successfully predicted outcomes from human clinical trials, both for positive (BILN-2061) and negative (HCV-371) outcomes.HCV-796, an orally dosed hepatitis C viral polymerase inhibitor developed from a different chemical series than HCV-371, has now been evaluated in in vitro and in vivo studies for anti-viral activity.The following studies were carried out with the animal model system and biochemical assays:--RNA dependent RNA polymerase inhibition assays and subgenomic replicon assays (study 1)--a pilot, proof-of-concept study of the anti-viral activity of HCV-796 at one dose in HCV infected chimeric mice (study 2)--assessment in infected

chimeric mice of the antiviral activity of HCV-796 compared to IFN a-2b or vehicle control (study 3)--assessment in infected chimeric mice of the antiviral activities of HCV-796 or IFN a-2b alone or in combination with each other (study 4) STUDY 1: In Vitro activity profile of HCV-796In vitro antiviral activity was evaluated in HCV replicon cells. Polymerase inhibition assays revealed an IC50 of 0.01 - 0.16 uM for genotype 1 and 0.22 - 1.7 uM for genotype 2, 3 and 4. In an in vitro subgenomic replicon assay, HCV=796 specifically reduced steady state levels of HCV RNA with IC50s of 5nM & 9 nM against genotypes 1a and 1b (Therapeutic Index >1100) and also reduced HCV protein. In the 1a replicon assay, HCV-796 reduced HCV RNA levels 3-4 log10 HCV copies/_g total RNA (EC50=4.5nM). Study 2 design: Pilot study of HCV-796 anti-viral activity in chimeric micedose: 50 mg/kg/doseadministration: 3

times a day, oralcourse: 5 days treatmentstudy animals: HCV-796: 6. Control: 6Assays: hAAT for monitoring human hepatocyte grafts, Taqman ABI 7300 real time PCR for HCV RNA quantification.RESULTS--mean serum HCV viral RNA decreased by 2.02 +/- 0.55 log after 5 days therapy in HCV-796 treatment group--HCV viral RNA level remained stable in vehicle control (3.94 +/- 0.8 to 3.71 +/- 1.0)--A significant difference in the net decrease of HCV viral RNA existed between HCV-796 and vehicle control (p=0.01, two-sided (unpaired) t-test).Study 3 design: Effect of polymerase inhibitor HCV-796 and IFN on HCV titer in chimeric miceDose: HCV-796 50/mg/kg per doseInterferon a-2b (IFN): 1350 IU/gm/dayAdministration: HCV-796 and vehicle 3 times per day by oral gavage; IFN once per day i.m.Course: 10 days treatmentStudy animals: 5 each of HCV-796, IFN and vehicle control groupsAssays: hAAT for

monitoring human hepatocyte grafts; Taqman ABI 7300 real time PCR for HCV RNA quantificationRESULTS--mean HCV viral RNA decreased 1.78 +/- 0.27 log after 10 day treatment course with HCV-796 versus 0.35 +/- log decrease in vehicle control (p=0.009)--mean HCV viral RNA decreased 1.11 +/- 0.2 log after 10 days treatment with IFNa-2b (p=0.04 vs vehicle control)--HCV viral titer rebounded in all HCV-796 treated animals following end of treatment (data not shownStudy 4 design: HCV-796 and Interferon a-2b combination study in chimeric miceDose: HCV-796 30/mg/kg/dose alone or combined with 1350 IU/gm IFNAdministration: HCV-796 3 doses daily by oral gavage; IFN daily i.m.Course: 18 days treatmentStudy animals: HCV-796: 7; IFN: 7, IFN+hCV-796 combination: 8; vehicle control: 7Assays: hAAT for monitoring human hepatocyte grafts, Taqman ABI 7300 real time PCR for HCV quantificationRESULTS--On

day 11, mean serum HCV viral NA decreased by 0.66 +/-0.16 log )HCV-796 30 mg/kg, p=0.013), 1.35 +/- 0.14 log (IFN 1350 IU/gm, p=0.0001), and 2.44 +/- 0.23 (IFN + HCV-796 combination, p=0.0001) versus 0.12 +/- 0.22 increase in vehicle control after 10 days of treatment--Serum HCV viral RNA titer reduction after 10 days of therapy was significantly greater in the combination group compared to the grouos receiving IFN or HCV-796 alone (p<0.05)In the SCID mouse model, mean plasma concentrations at 8 hr after a single dose and dosing for 5 days with 50 mg/kg were 5- and 12-fold, respectively, above replicon EC50 (t1/2=2hr). The specific antiviral activity of HCV-796 is further confirmed by the viral rebound to baseline within 1 week of stopping treatment. The authors summarized: HCV-796 represents a potential antiviral for the treatment of HCV infection in humans. HCV-796, a novel non-nucleoside inhibitor of

the hepatitis C virus RNA-dependent RNA polymerase, demonstrated specific polymerase activity with IC50 values of 0.01 - 0.16 uM against genotype 1 and IC50 values of 0.22 to 1,7 uM against genotype 2, 3, and 4 enzymes. The compound also exhibited high activity in replicon systems and multiple treatments of genotype 1b replicon cells yielded a 3 to 4 log reduction in HCV viral RNA levels. The in vitro activity paralled in vivo results obtained with the HCV-infected chimeric mouse model. The mean HCV viral load in mice was reduced by 1.78 to 1.88 log after 5 to 10 days therapy with 50 mg/kg dose of HCV-796 compared to a mean 1.11 log decrease obtained with interferon a-2b treatment for 10 days. The combination of 30 mg/kg HCV-796 with interferon a-2b (1350IU/gm/day) resulted in a mean 2.44 log decrease in HCV viral RNA which was significantly greater than the decrease obtained with either HCV-796 or interferon a-2b

alone (0.66 or 1.35 log, respectively; p<0.05).This small animal model has previously proven predictive of clinical treatment impact for antiviral compounds for HCV as demonstrated by positive outcomes in the mouse model with interferon a-2b and a protease inhibitor (BILN-2061) and by negative outcomes with a polymerase inhibitor HCV-371 in both the mouse model (2) and a phase 1b clinical trial (4).The predictive value of the mouse model has now also been confirmed by the positive outcomes with HCV-796 in the model and in vitro studies and the recently announced preliminary data from a clinical phase 1b trial of HCV-796 and pegylated interferon combination therapy in which a mean viral load reduction across all combination groups of between 3.3 to 3.5 log was obtained at day 14 compared to a 1.7 log decrease obtained with interferon alone (6). Tim Parsons knoxville,tn 37931 865-588-2465 x107 work www.knoxville1.com All-new - Fire up a more powerful email and get things done faster. Jackie